December 13, 2018
Diabetes management startup Tidepool has just locked in a $6 million grant from the Leona M. and Harry B. Helmsley Charitable Trust and JDRF in order to kick off develop an app for hybrid closed-loop automated insulin delivery.
Eventually the company plans to bring the software to market as an FDA-regulated mobile app. Right now the plans are to build an app that is specifically designed to help...
February 5, 2018
The Juvenile Diabetes Research Foundation (JDRF) and Massachusetts-based Cam Med, a company specializing in microfluidic-based drug delivery technologies, announced a partnership today focused on development of a thin, flexible, patch-based insulin pump for artificial pancreas systems.
"JDRF is excited to partner with Cam Med on improving insulin delivery hardware,” Jaime Giraldo, program...
January 25, 2018
The Juvenile Diabetes Research Foundation (JDRF) has partnered with South Korean medical device company EOFlow to accelerate the development of EOPatch, the company's wearable insulin pump.
"JDRF is working hard to reduce the burden of living with Type 1 diabetes while we search for ways to cure this disease," Jaime Giraldo, Ph.D., research scientist at JDRF, said in a statement. "Innovation in...
October 18, 2017
Efforts to build artificial pancreas (AP) systems under open protocols will get a boost from JDRF, a multinational group that funds Type 1 diabetes research and other programs. The organization has announced a new initiative to not only provide funds for these DIY and frequently reverse engineered projects, but will also provide the regulatory and liability guidance necessary for a public release...
August 21, 2017
IBM and JDRF, a global organization funding Type 1 diabetes research, are joining forces. The collaboration will develop machine learning methods and use them to analyze years of Type 1 research data to pinpoint the factors that can contribute to the onset of the condition in children.
Type 1 diabetes -- T1D for short -- affects about 1.25 million Americans, and to date does not have a cure....
January 30, 2017
Milpitas, California-based Bigfoot Biomedical, a diabetes management company working on their first product, announced an investment from the Juvenile Diabetes Research Foundation (JDRF)’s newly launched venture fund, T1D, focused on early stage companies working on type 1 diabetes. The terms of the investment were not disclosed, but Bigfoot previously raised $35.5 million.
The funding will be...